GO:2001039 negative regulation of cellular response to drug: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001039 describes the biological process that reduces or restrains a cell's response to a drug, thereby modulating drug sensitivity, resistance, and toxicity.
• Key molecular players include DNA repair regulators such as DTX3L and TIRR, which influence PARP inhibitor sensitivity, and RNF213, which regulates homologous recombination and chemosensitivity.
• Negative regulators of the type I interferon pathway, such as TRBP, can suppress antiviral stress granule formation and modulate drug responses.
• The process is highly relevant to cancer therapy, where it can drive chemoresistance, and to antiviral and anti-inflammatory drug development.
• Experimental dissection of GO:2001039 relies on CRISPR knockout, point mutation, knock-in, and overexpression models combined with functional assays.
• Understanding this process supports identification of biomarkers and combination strategies to overcome drug resistance.
Description
The Gene Ontology term GO:2001039, negative regulation of cellular response to drug, defines any process that stops, prevents, or reduces the rate or extent of a cellular response to a drug. In practical terms, it encompasses molecular events that make a cell less responsive to a pharmacological agent, whether by limiting drug uptake, enhancing drug efflux, activating survival pathways, or promoting DNA repair. This term is critical for researchers because it directly impacts drug efficacy, resistance mechanisms, and the development of combination therapies. For example, DTX3L-mediated regulation of TIRR influences DNA repair pathway choice and PARP inhibitor sensitivity, illustrating how negative regulation can determine therapeutic outcomes. Similarly, RNF213 phosphorylation by ATM regulates homologous recombination repair and chemosensitivity, highlighting a direct link between this process and drug response. The type I interferon pathway also contains negative regulators that modulate cellular responses to antiviral drugs and immunomodulators. Thus, GO:2001039 provides a conceptual framework for understanding how cells evade drug action and for designing strategies to overcome resistance.
negative regulation of cellular response to drug At A Glance
| GO ID | GO:2001039 |
|---|---|
| GO term | negative regulation of cellular response to drug |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Reduces or restrains cellular responsiveness to pharmacological agents, contributing to drug resistance or reduced drug efficacy |
| Related processes | DNA repair, interferon signaling, oxidative stress response, unfolded protein response |
| Key regulators | DTX3L, TIRR, RNF213, TMEM166, TRBP, PIK3IP1 |
| Disease relevance | Cancer chemoresistance, antiviral resistance, inflammatory disorders |
What Is GO:2001039?
In our own words, GO:2001039 refers to any biological process that decreases the frequency, rate, or extent of a cell's response to a drug. This includes mechanisms that dampen drug-induced signaling, enhance drug inactivation or efflux, promote cell survival, or accelerate repair of drug-induced damage. It is a negative regulatory process that opposes the positive regulation of cellular response to drug, ultimately reducing drug sensitivity or conferring resistance.
Why Is negative regulation of cellular response to drug Important in Cell Biology?
GO:2001039 is important because it governs a cell's ability to withstand drug treatment, a central problem in cancer therapy, infectious disease, and pharmacology. Negative regulation of drug response can lead to chemoresistance, reduce the effectiveness of targeted therapies, and complicate treatment regimens. Understanding the molecular players and pathways involved offers opportunities to predict patient responses, identify biomarkers, and develop combination therapies that bypass or inhibit these negative regulators.
• Contributes to chemoresistance in cancers treated with PARP inhibitors, platinum agents, and other DNA-damaging drugs.
• Modulates sensitivity to sorafenib in hepatocellular carcinoma through unfolded protein response regulation.
• Influences antiviral drug efficacy via negative regulation of the type I interferon pathway.
• Affects oxidative stress responses and drug-induced toxicity through regulators like p21 and MiTF.
• Provides targets for combination therapies aimed at overcoming drug resistance.
• Helps explain inter-patient variability in drug response.
• Guides development of CRISPR-based screens to identify novel negative regulators.
• Supports precision medicine by linking genetic alterations to drug sensitivity.
• Relevant to neurodegenerative and inflammatory diseases where drug response modulation is critical.
• Offers a framework for studying cellular adaptation to pharmacological stress.
What Happens During negative regulation of cellular response to drug?
Drug Sensing and Initial Signaling
In simple terms: The cell first detects the drug and triggers a response; negative regulation starts by dampening this early signal.
Upon drug exposure, cells activate signaling cascades that would normally lead to drug-induced effects such as DNA damage, oxidative stress, or apoptosis. Negative regulation of this response can occur at the sensing stage, where proteins like TRBP inhibit PKR-mediated antiviral stress granule formation, thereby reducing the cellular response to antiviral drugs. Similarly, negative regulators of the type I interferon pathway can suppress interferon signaling, limiting the efficacy of immunomodulatory drugs.
DNA Repair Pathway Choice
In simple terms: When drugs damage DNA, the cell chooses how to repair it; negative regulation can favor repair pathways that promote survival.
DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity, illustrating how negative regulation of drug response can shift repair toward homologous recombination or other pathways that confer resistance. RNF213 phosphorylation by ATM-mediated ubiquitination of RPA1 regulates homologous recombination repair and chemosensitivity, further demonstrating that DNA repair modulation is a key mechanism of negative regulation.
Survival and Stress Adaptation
In simple terms: The cell activates survival programs to withstand drug stress; negative regulators enhance these programs.
TMEM166 negatively regulates the unfolded protein response to affect hepatocellular carcinoma cell growth and sorafenib resistance, showing that suppression of stress responses can reduce drug efficacy. PIK3IP1, a negative regulator of PI3K signaling, modulates cell survival and proliferation, and its dysregulation can influence drug responses in various diseases. Oxidative stress response regulators such as p21 and MiTF also contribute to cellular adaptation to drug-induced stress.
Drug Efflux and Metabolism
In simple terms: Cells can pump drugs out or break them down; negative regulation can increase these processes.
Although specific efflux pumps are not directly cited in the provided literature, the general principle of negative regulation of drug response includes enhanced drug efflux and metabolism. The cited studies focus on DNA repair, interferon signaling, and stress responses, which indirectly affect drug sensitivity. These mechanisms collectively reduce intracellular drug activity and promote survival.
Integration of Negative Regulatory Signals
In simple terms: Multiple negative regulators work together to fine-tune the drug response.
The interplay between DNA repair, interferon signaling, and stress response pathways determines the overall cellular response to drugs. For instance, DTX3L and RNF213 both influence DNA repair and chemosensitivity, suggesting coordinated regulation. TRBP and other interferon pathway regulators modulate antiviral responses, which can affect drug efficacy. This integration ensures that cells can adapt to pharmacological challenges.
Key Genes Involved in GO:2001039 negative regulation of cellular response to drug
The following genes and proteins have been experimentally linked to negative regulation of cellular response to drug, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DTX3L | Mediates TIRR nuclear export and degradation, regulating DNA repair pathway choice | PARP inhibitor sensitivity; chemoresistance |
| TIRR | DNA repair regulator, target of DTX3L | Homologous recombination, drug response |
| RNF213 | Phosphorylated by ATM, ubiquitinates RPA1, regulates homologous recombination | Chemosensitivity, DNA repair |
| RPA1 | Single-stranded DNA-binding protein, ubiquitinated by RNF213 | Homologous recombination, drug response |
| TMEM166 | Negatively regulates unfolded protein response | Sorafenib resistance in hepatocellular carcinoma |
| TRBP | Modulates RLR signaling by inhibiting PKR-mediated stress granule formation | Antiviral drug response |
| PKR | Antiviral stress granule formation, inhibited by TRBP | Interferon signaling, drug response |
| PIK3IP1 | Negative regulator of PI3K signaling | Cell survival, drug resistance |
| p21 | Regulated by p53 and Rb in oxidative stress response | Cellular response to oxidative stress |
| MiTF | Transcriptional regulation of APE-1/Ref-1 | Reactive oxygen species response |
| APE-1/Ref-1 | DNA repair and redox regulation, target of MiTF | Oxidative stress, drug response |
| ATM | Kinase that phosphorylates RNF213 | DNA damage response, chemosensitivity |
| TIRR | Interacts with DTX3L | DNA repair, PARP inhibitor sensitivity |
| RNF213 | E3 ubiquitin ligase | Homologous recombination, drug response |
| TRBP | Double-stranded RNA-binding protein | Interferon pathway, antiviral response |
| PKR | Protein kinase R | Antiviral stress granule formation |
| TMEM166 | Transmembrane protein 166 | Unfolded protein response, sorafenib resistance |
| PIK3IP1 | PI3K-interacting protein 1 | PI3K signaling, disease regulation |
How Is negative regulation of cellular response to drug Regulated?
The process of negative regulation of cellular response to drug is itself regulated at multiple levels. For example, DTX3L-mediated regulation of TIRR is controlled by nuclear export and degradation signals. RNF213 activity is regulated by ATM-mediated phosphorylation, which in turn affects homologous recombination and chemosensitivity. TRBP modulates RLR signaling by inhibiting PKR-mediated antiviral stress granule formation, a process that can be influenced by viral infection and interferon signaling. Additionally, TMEM166 negatively regulates the unfolded protein response, and its expression levels affect sorafenib resistance. These regulatory mechanisms ensure that the negative regulation of drug response is dynamic and context-dependent.
negative regulation of cellular response to drug and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DTX3L | PARP inhibitor resistance in cancer | CRISPR knockout in cancer cell lines, xenograft models |
| RNF213 | Chemosensitivity in cancers | Point mutation knock-in, organoids |
| TMEM166 | Sorafenib resistance in hepatocellular carcinoma | Overexpression and knockout in HCC cell lines |
| TRBP | Antiviral drug resistance | Knockout in immune cells, viral infection models |
| PIK3IP1 | Inflammatory and metabolic diseases | Knockout mice, cell-based assays |
Cancer Chemoresistance
Negative regulation of cellular response to drug is a major contributor to chemoresistance in cancer. DTX3L-mediated regulation of TIRR influences PARP inhibitor sensitivity, and high DTX3L levels may confer resistance to PARP inhibitors in breast and ovarian cancers. RNF213 phosphorylation by ATM regulates homologous recombination repair and chemosensitivity, suggesting that RNF213 status could predict response to platinum-based chemotherapy. TMEM166 negatively regulates the unfolded protein response and affects sorafenib resistance in hepatocellular carcinoma, highlighting its potential as a therapeutic target.
Antiviral Drug Resistance
Negative regulators of the type I interferon pathway, such as TRBP, can suppress antiviral stress granule formation and limit the efficacy of antiviral drugs. This mechanism may contribute to viral evasion of interferon-based therapies and reduce the effectiveness of immunomodulatory treatments.
Oxidative Stress and Inflammatory Diseases
Regulators like p21 and MiTF modulate cellular responses to oxidative stress, which can affect drug-induced toxicity and inflammatory conditions. PIK3IP1, a negative regulator of PI3K signaling, is implicated in various diseases and may influence drug responses in inflammatory and metabolic disorders.
From negative regulation of cellular response to drug-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of DTX3L sensitize cancer cells to PARP inhibitors? | CRISPR knockout in BRCA-mutant cancer cell lines |
| Does point mutation in RNF213 affect homologous recombination and chemosensitivity? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of TMEM166 reduce sorafenib resistance? | CRISPR overexpression in hepatocellular carcinoma cells |
| Does knockout of TRBP enhance antiviral stress granule formation? | CRISPR knockout in macrophages or epithelial cells |
| Does knock-in of a tagged PIK3IP1 alter PI3K signaling? | CRISPR tagged knock-in in cell lines |
| Does knockout of p21 affect oxidative stress response? | CRISPR knockout in fibroblasts or cancer cells |
How to Study the negative regulation of cellular response to drug Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on drug response | Identify negative regulators |
| CRISPR knock-in | Precise mutation effects | Validate point mutations |
| RNA-seq | Transcriptional changes | Profile drug response pathways |
| Proteomics | Protein abundance and modifications | Study DNA repair and signaling |
| Immunofluorescence | Protein localization and stress granules | Visualize TRBP and PKR |
| Western blot | Protein expression and phosphorylation | Validate knockout/knock-in |
| Drug sensitivity assays | IC50 and cell viability | Measure chemoresistance |
| Flow cytometry | Apoptosis and cell cycle | Assess drug-induced cell death |
CRISPR Screens for Negative Regulators
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or overexpression alters cellular response to a drug. For example, screening and validation of negative regulators of the type I interferon pathway identified TRBP as a modulator of antiviral stress granule formation. Such screens are powerful for discovering novel negative regulators of drug response.
Functional Validation with Knockout and Knock-in Models
After candidate identification, CRISPR knockout and knock-in models are used to validate gene function. DTX3L knockout and TIRR knock-in studies demonstrated their roles in DNA repair pathway choice and PARP inhibitor sensitivity. RNF213 point mutations were introduced to study their effects on homologous recombination and chemosensitivity.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can reveal global changes in gene expression and protein abundance upon drug treatment in cells with specific genetic alterations. For instance, TMEM166 overexpression was shown to affect unfolded protein response genes and sorafenib resistance. Such profiling helps elucidate downstream mechanisms of negative regulation.
Imaging and Stress Granule Assays
Fluorescence microscopy can visualize stress granule formation and localization of proteins like TRBP and PKR. TRBP inhibits PKR-mediated antiviral stress granule formation, which can be monitored by imaging. These assays provide spatial and temporal insights into negative regulation.
How CRISPR Can Be Used to Study GO:2001039 negative regulation of cellular response to drug
Knockout
CRISPR knockout is used to delete genes involved in negative regulation of drug response, such as DTX3L, to assess whether loss of function sensitizes cells to drugs like PARP inhibitors. Knockout of TRBP can enhance antiviral stress granule formation and alter drug responses.
Point Mutation
Point mutation knock-in allows precise modeling of clinically relevant mutations, such as those in RNF213, to study their impact on homologous recombination and chemosensitivity. This approach helps distinguish loss-of-function from gain-of-function effects.
Knock-in
Knock-in of tagged or reporter genes enables tracking of proteins like TIRR or PIK3IP1 in live cells, facilitating studies of their localization, stability, and interactions under drug treatment.
Overexpression
CRISPR activation or cDNA overexpression is used to increase levels of negative regulators such as TMEM166 to test whether overexpression enhances drug resistance. Overexpression models are valuable for gain-of-function studies.
How EDITGENE Supports negative regulation of cellular response to drug Research
Researchers studying negative regulation of cellular response to drug-related genes often need to determine whether a candidate gene is causally involved in modulating drug sensitivity. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process, from knockout to precise point mutations and library screens.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cellular response to drug research.
Frequently Asked Questions About negative regulation of cellular response to drug
What is GO:2001039?
GO:2001039 is the Gene Ontology term for negative regulation of cellular response to drug, describing any process that reduces or restrains a cell's response to a pharmacological agent.
What genes are involved in negative regulation of cellular response to drug?
Key genes include DTX3L, TIRR, RNF213, TMEM166, TRBP, PIK3IP1, p21, and MiTF, among others.
How does negative regulation of drug response contribute to chemoresistance?
It can enhance DNA repair, suppress stress responses, or inhibit interferon signaling, allowing cancer cells to survive drug treatment.
What experimental models are used to study GO:2001039?
CRISPR knockout, point mutation knock-in, overexpression, and library screens are commonly used.
Which diseases are associated with negative regulation of cellular response to drug?
Cancer chemoresistance, antiviral drug resistance, and inflammatory diseases are linked to this process.
How can CRISPR screens identify negative regulators of drug response?
Genome-wide knockout or activation screens can reveal genes whose loss or overexpression alters drug sensitivity, as shown for interferon pathway regulators.
What is the role of DTX3L in drug response?
DTX3L mediates TIRR nuclear export and degradation, regulating DNA repair pathway choice and PARP inhibitor sensitivity.
How does RNF213 affect chemosensitivity?
RNF213 phosphorylation by ATM regulates homologous recombination repair and chemosensitivity.
What is the link between TMEM166 and sorafenib resistance?
TMEM166 negatively regulates the unfolded protein response, affecting hepatocellular carcinoma cell growth and sorafenib resistance.
How does TRBP modulate antiviral drug response?
TRBP modulates RLR signaling by inhibiting PKR-mediated antiviral stress granule formation, which can affect antiviral drug efficacy.
Conclusion
GO:2001039, negative regulation of cellular response to drug, is a critical biological process that modulates drug efficacy and resistance. Through diverse mechanisms including DNA repair regulation, interferon pathway suppression, and stress response adaptation, cells can reduce their sensitivity to pharmacological agents. Understanding these pathways offers opportunities for therapeutic intervention, biomarker discovery, and combination strategies. EDITGENE provides comprehensive CRISPR services to study this process and accelerate drug development.
References
- 1. Ye Q et al.. 2024. DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity.. Nat Commun 15(1):10596 PMID: 39632881
- 2. Pang Z et al.. 2025. Screening and Validation of Negative Regulators of the Type I Interferon Pathway.. Adv Biol (Weinh) 9(11):e00736 PMID: 40828666
- 3. Hu D et al.. 2025. Phosphorylation of RNF213 by ATM-mediated ubiquitination of RPA1 regulates homologous recombination repair and chemosensitivity.. Cell Death Dis 16(1):749 PMID: 41120267
- 4. Yin Y et al.. 1999. Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress.. Mol Carcinog 24(1):15-24 PMID: 10029406
- 5. Liu F et al.. 2009. MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1.. J Invest Dermatol 129(2):422-31 PMID: 18971960
- 6. Li T et al.. 2025. TMEM166 negatively regulates unfolded protein response to affect hepatocellular carcinoma cell growth and sorafenib resistance.. Cell Death Dis 16(1):794 PMID: 41193471
- 7. Jia Y et al.. 2024. PIK3IP1: structure, aberration, function, and regulation in diseases.. Eur J Pharmacol 977:176753 PMID: 38897445
- 8. Onomoto K et al.. 2025. TRBP modulates RLR signaling by inhibiting PKR-mediated antiviral stress granule formation.. Sci Rep 15(1):20678 PMID: 40593223
